Ranbaxy reports steady Q1 numbers; helped by strong domestic sales
By Ranbaxy Laboratories, th | 20 Apr 2006
The company has reported a consolidated net profit of Rs71.4 crore, or Rs1.91 per share, for the quarter ended 31 March 2006, a marginal increase of under a per cent when compared to Rs70.8 crore or Rs1.89 per share reported for the same quarter of previous year.
Consolidated revenues for the quarter rose 12.03 per cent to Rs1,275.3 crore from Rs1,138.3 crore for the previous year quarter.
Ranbaxy's consolidated EBITDA for the quarter increased 16.24 per cent to Rs148.2 crore from Rs127.5 crore during the prior year quarter. EBITDA margins as a percentage of consolidated revenues improved marginally to 11.62 per cent from 11.2 per cent during the previous year quarter.
For the previous quarter ended December 2005, Ranbaxy had reported a consolidated net profit of Rs68.6 crore on total revenues of Rs1,429.1 crore. Consolidated EBITDA for the December 2005 was at Rs65.4 and EBITDA margins were at 4.58 per cent. The company had benefited from a tax write back of Rs37.7 crore during that quarter.
The company said sales in the US markets rose 10 per cent during the quarter after many quarters of declines, taking the company's share in the US generics market to 2.7 per cent from 2.4 per cent during the December 2005 quarter.
The company improved its domestic market share to 4.82 per cent with strong sales growth during the quarter. The company launched 2 new drugs for the diabetes and asthma during the quarter.
For the year ended 31 December 2005, Ranbaxy has reported an audited consolidated net profit of Rs261.7 crore, or Rs6.85 per share, a decline of 62.54 per cent from the previous year figure of Rs698.6 crore or Rs18.74 per share.
Full year consolidated revenues for 2005 were lower by 2.35 per cent at Rs5,188 crore as compared to Rs5,313 crore.
The company has made 3 significant acquisitions in Europe recently which were funded through a $440 million FCCB issue.
